Serono and CancerVax Corporation to collaborate for the development and commercializatian of a new cancer drug for malanoma

20-Dec-2004 - Serono and CancerVax Corporation announced a worldwide collaboration for the development and commercialization of Canvaxin(TM) , an investigational specific active immunotherapy product being developed for the treatment of advanced-stage melanoma, a deadly form of skin cancer. Canvaxin(TM) is ...

Proteome Systems enters agreement to acquire US-based Pharmaceutical Company, Eukarion, Inc.

20-Dec-2004 - Proteome Systems announced the signing of an agreement to acquire the US-based pharmaceutical company, Eukarion Inc. The acquisition will bring to Proteome Systems several families of pre-clinical antioxidant drugs, and staff with deep experience in the development of pharmaceuticals who will ...

Prometic Finalizes Major Technology Licencing Agreement in Tunisia

20-Dec-2004 - ProMetic Life Sciences Inc. announced the closing of a collaborative agreement with Tunisian partners. ProMetic's Enabling Technology has been licensed to BioMena S.A., a newly-formed private company whose corporate mission will be to manufacture biopharmaceuticals for the treatment of anemia, ...

Genmap's HuMax-CD20 to Treat CLL Awarded Fast Track Status From FDA

17-Dec-2004 - Genmab A/S announced that HuMax(TM)-CD20 has been designated a Fast Track Product by the US Food and Drug Administration (FDA). This designation covers patients with chronic lymphocytic leukemia (CLL) who have failed fludarabine therapy. This patient group includes those who are refractory to ...

Diatos Moves Its Lead Drug Toward Clinical Trials in Europe

17-Dec-2004 - Diatos S.A. announced the positive review and regulatory clearance of its lead drug DTS-201 Investigational Drug application by the Ethics Committee of Toulouse 1 (France). The AFSSAPS (French Health Products Safety Agency) has already been notified and the company will conduct this initial Phase ...

Biovitrum AB and Discovery Partners International, Inc. form research alliance

16-Dec-2004 - Alliance Stockholm and San Diego. Biovitrum AB and Discovery Partners International, Inc. announced that they have entered into a drug discovery and development alliance. Biovitrum and Discovery Partners will work together to identify small molecule lead compounds suitable for advancing targets ...

The Human Side of Science: What is the Archetypal Researcher Personality?

16-Dec-2004 - Arlington. Are there some personalities that are better suited than others to a scientific career? To provide insight into this issue, The Science Advisory Board created the first-ever psychological profile of life science researchers, the Scientific Personality Assessment (SPA). The SPA is meant ...

South Korea poised to become a major pharmaceutical industry player?

15-Dec-2004 - Despite the ongoing risks and costs of drug development, as well as a continuing of a general 'low ebb' in the industry, new players are using partnering tactics to build a presence in the global pharmaceutical market, most notably South Korea. Like many other emerging pharmaceutical sectors in ...

$43 million grant from Gates Foundation brings together unique collaboration for antimalarial drug

Effort could significantly reduce cost, boost aupplies of artemisinin

15-Dec-2004 - A $42.6 million grant from the Bill & Melinda Gates Foundation to the Institute for OneWorld Health, the first nonprofit pharmaceutical company in the United States, will create a powerful new approach to developing a more affordable, accessible cure for malaria, which kills more than a million ...

Oxford BioMedica Licenses Retroviral Ex Vivo Gene Delivery Technology to MolMed SpA

15-Dec-2004 - Oxford BioMedica and MolMed SpA (Milan, Italy) today announced a licence agreement for Oxford BioMedica's retroviral ex vivo gene delivery technology. The agreement provides MolMed with rights to utilise this technology in the development of MolMed's product pipeline. Under the agreement, Oxford ...